Ascentage Pharma Group International (HKG:6855) narrowed its attributable loss in 2024 to 405.4 million yuan from 925.6 million yuan in the year-ago period, a Thursday filing with the Hong Kong bourse said.
Loss per share stood at 1.34 yuan, narrower than 3.28 yuan in 2023.
The drugmaker's revenue for the year increased by 342% to 980.7 million yuan from 222 million yuan a year prior.
The higher revenue was partly attributable to intellectual property income from Takeda Pharmaceuticals International and the strong sales growth of olverembatinib.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。